Degeneration of Macula and Posterior Pole Clinical Trial
Official title:
Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis.
Significant difference in the parameter settings of early optical coherence tomography (OCT spectal domain) in patients with subfoveal neovascular membrane realacionada age after treatment with a single intravitreal injection of Lucentis.
Assessment in early changes in the parameters of optical coherence tomography (OCT spectral
domain) in patients with subfoveal neovascularization secondary to age-related degeneration
after treatment with a single intravitreal injection of Lucentis.
Age-related macular degeneration (AMD) leading cause of blindness over 50 years in developed
Western countries. Its prevalence increases with age affecting about 8.5 to 27.9% of the
population over 75 years. Its incidence has increased 30-40% in recent decades, in spite of
eye diseases such as cataracts and glaucoma, which reach the same population group, have
shown apparently reduced their records.
Although approximately 80% of patients with AMD have the neovascular form does not, the
neovascular form is responsible for almost 90% of severe visual loss resulting from AMD. It
creates great socioeconomic impact, becoming a public health problem.
Quantitative analysis of OCT has shown increasing clinical importance with the development
of anti-VEGF therapy to evaluate the outcome of the treatment of neovascular AMD.
Relatively few studies in AMD has been proposed to examine the correlation between the
morphological parameters of the OCT and BCVA in a systematic way.
It is important to assess the impact that different OCT parameters have on visual acuity as
early as 7 days after intravitreal injection of ranibizumab in patients with AMD to define
which of these parameters correlate better with the AV and prognosis. It is also unknown
which patients' perception of the effectiveness of treatment in early stage. For this
evaluation, we apply the visual function questionnaire (VFQ - 25) 1 and 7 days after
treatment.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care